Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles Enable a Stable Non-Spilling Loading of T Cells and Their Magnetic Accumulation.

adoptive T cell transfer immune therapy magnetic targeting nanomedicine solid tumor superparamagnetic iron oxide nanoparticles (SPIONs) targeted transport

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
17 Aug 2021
Historique:
received: 14 06 2021
revised: 10 08 2021
accepted: 13 08 2021
entrez: 27 8 2021
pubmed: 28 8 2021
medline: 28 8 2021
Statut: epublish

Résumé

T cell infiltration into a tumor is associated with a good clinical prognosis of the patient and adoptive T cell therapy can increase anti-tumor immune responses. However, immune cells are often excluded from tumor infiltration and can lack activation due to the immune-suppressive tumor microenvironment. To make T cells controllable by external forces, we loaded primary human CD3+ T cells with citrate-coated superparamagnetic iron oxide nanoparticles (SPIONs). Since the efficacy of magnetic targeting depends on the amount of SPION loading, we investigated how experimental conditions influence nanoparticle uptake and viability of cells. We found that loading in the presence of serum improved both the colloidal stability of SPIONs and viability of T cells, whereas stimulation with CD3/CD28/CD2 and IL-2 did not influence nanoparticle uptake. Furthermore, SPION loading did not impair cytokine secretion after polyclonal stimulation. We finally achieved 1.4 pg iron loading per cell, which was both located intracellularly in vesicles and bound to the plasma membrane. Importantly, nanoparticles did not spill over to non-loaded cells. Since SPION-loading enabled efficient magnetic accumulation of T cells in vitro under dynamic conditions, we conclude that this might be a good starting point for the investigation of in vivo delivery of immune cells.

Identifiants

pubmed: 34439296
pii: cancers13164143
doi: 10.3390/cancers13164143
pmc: PMC8394404
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Else Kröner-Fresenius-Stiftung
ID : 2018_A88
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB TRR 305 - B05, DU5485-1
Organisme : Emerging Fields Initiative EFI-BIG-Thera
Organisme : Staedtler Stiftung

Références

Magn Reson Med. 2006 Sep;56(3):498-508
pubmed: 16897768
Nanoscale Res Lett. 2018 Oct 25;13(1):339
pubmed: 30361809
Nat Commun. 2019 May 28;10(1):2341
pubmed: 31138801
NMR Biomed. 2010 Jul;23(6):601-9
pubmed: 20661874
Nat Nanotechnol. 2017 Jul 6;12(7):598-600
pubmed: 28681852
Nat Nanotechnol. 2011 Nov 06;7(1):62-8
pubmed: 22056728
Front Immunol. 2019 Aug 30;10:2073
pubmed: 31543880
Nanotoxicology. 2013 May;7(3):235-50
pubmed: 22264124
J Nanobiotechnology. 2013;11 Suppl 1:S7
pubmed: 24564857
Oncoimmunology. 2017 Jul 20;6(10):e1345403
pubmed: 29123957
J Clin Pathol. 1986 Jun;39(6):585-9
pubmed: 3722412
Cytometry. 1990;11(2):231-8
pubmed: 1690625
Int J Nanomedicine. 2012;7:5577-91
pubmed: 23144561
J Neuroimmunol. 2013 Nov 15;264(1-2):71-83
pubmed: 24045166
ACS Nano. 2019 Feb 26;13(2):1469-1478
pubmed: 30763076
Eur Radiol. 2008 Jun;18(6):1087-95
pubmed: 18286290
J Epidemiol Glob Health. 2019 Dec;9(4):217-222
pubmed: 31854162
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Int J Nanomedicine. 2019 Oct 24;14:8421-8432
pubmed: 31749616
Nat Rev Cancer. 2003 Sep;3(9):666-75
pubmed: 12951585
Chem Soc Rev. 2016 May 3;45(9):2440-57
pubmed: 26862602
J Nanobiotechnology. 2019 Jan 22;17(1):14
pubmed: 30670029
Theranostics. 2016 Sep 2;6(11):2000-2014
pubmed: 27698936
ACS Nano. 2015 Aug 25;9(8):8142-56
pubmed: 26135229
ACS Nano. 2013 Sep 24;7(9):7442-7
pubmed: 24490875
Nat Rev Cancer. 2017 Jan;17(1):20-37
pubmed: 27834398
ACS Cent Sci. 2016 Jul 27;2(7):434-7
pubmed: 27504489
Nanomedicine. 2013 Oct;9(7):961-71
pubmed: 23669367
Pharmaceutics. 2020 Aug 27;12(9):
pubmed: 32867162
Science. 2008 Aug 15;321(5891):974-7
pubmed: 18703743
Int J Nanomedicine. 2015 Jun 26;10:4185-201
pubmed: 26170658
Chem Rev. 2011 Sep 14;111(9):5610-37
pubmed: 21688848
ACS Nano. 2012 Jul 24;6(7):5845-57
pubmed: 22721453
Int J Pharm. 2015 Jul 25;490(1-2):190-9
pubmed: 25997662
J Nanobiotechnology. 2019 Aug 6;17(1):87
pubmed: 31387604
Nat Commun. 2015 Aug 18;6:8009
pubmed: 26284300
Int J Nanomedicine. 2018 Feb 27;13:1119-1137
pubmed: 29520140
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):698-703
pubmed: 18182491
Am J Clin Oncol. 2013 Jun;36(3):224-31
pubmed: 22495453
ACS Nano. 2021 Jun 24;:
pubmed: 34165964
Transplantation. 2003 Oct 15;76(7):1043-6
pubmed: 14557750
Cancer Immunol Immunother. 2008 Feb;57(2):271-80
pubmed: 17646988
Cancer. 1994 Mar 15;73(6):1731-7
pubmed: 8156501
Nat Commun. 2020 Jan 10;11(1):180
pubmed: 31924779
Mol Pharm. 2014 Oct 6;11(10):3642-55
pubmed: 25166282
Nanomedicine. 2012 Nov;8(8):1345-54
pubmed: 22406186
Nanoscale. 2015 Mar 7;7(9):3954-8
pubmed: 25652717
J Clin Oncol. 2011 Jun 20;29(18):2493-8
pubmed: 21576633
Biomaterials. 2008 Aug;29(22):3161-74
pubmed: 18455232
Haematologica. 2014 Jul;99(7):1212-9
pubmed: 24727818
Phys Rev E Stat Nonlin Soft Matter Phys. 2007 Apr;75(4 Pt 1):041906
pubmed: 17500920
Nat Nanotechnol. 2009 Sep;4(9):577-80
pubmed: 19734930
Nanomedicine (Lond). 2015;10(7):1063-76
pubmed: 25929565
Nat Nanotechnol. 2009 Sep;4(9):546-7
pubmed: 19734922
Biomaterials. 2010 Jul;31(20):5366-71
pubmed: 20382425
Biomater Sci. 2019 Feb 26;7(3):789-797
pubmed: 30633266
Blood. 2012 Jun 28;119(26):6226-33
pubmed: 22592608
Nat Mater. 2009 Jul;8(7):543-57
pubmed: 19525947
J Immunol Methods. 2001 Oct 1;256(1-2):89-105
pubmed: 11516758
Int J Nanomedicine. 2016 May 12;11:2021-37
pubmed: 27274233
J Immunol Methods. 2006 Jul 31;314(1-2):123-33
pubmed: 16860821
Cell Tissue Res. 2004 Jun;316(3):315-23
pubmed: 15103550
Nanotechnol Sci Appl. 2021 Apr 06;14:91-100
pubmed: 33854305
Cells. 2020 Feb 01;9(2):
pubmed: 32024193
Cancer Res. 2003 Oct 15;63(20):6838-46
pubmed: 14583481
ACS Nano. 2016 Aug 23;10(8):7627-38
pubmed: 27419260

Auteurs

Philipp Boosz (P)

Department of Otorhinolaryngology, Head and Neck Surgery, Section of Experimental Oncology and Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung Professorship, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.

Felix Pfister (F)

Department of Otorhinolaryngology, Head and Neck Surgery, Section of Experimental Oncology and Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung Professorship, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.

Rene Stein (R)

Department of Otorhinolaryngology, Head and Neck Surgery, Section of Experimental Oncology and Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung Professorship, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.

Bernhard Friedrich (B)

Department of Otorhinolaryngology, Head and Neck Surgery, Section of Experimental Oncology and Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung Professorship, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.

Lars Fester (L)

Institute of Anatomy and Cell Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.

Julia Band (J)

Department of Otorhinolaryngology, Head and Neck Surgery, Section of Experimental Oncology and Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung Professorship, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.

Marina Mühlberger (M)

Department of Otorhinolaryngology, Head and Neck Surgery, Section of Experimental Oncology and Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung Professorship, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.

Eveline Schreiber (E)

Department of Otorhinolaryngology, Head and Neck Surgery, Section of Experimental Oncology and Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung Professorship, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.

Stefan Lyer (S)

Department of Otorhinolaryngology, Head and Neck Surgery, Section of Experimental Oncology and Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung Professorship, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.

Diana Dudziak (D)

Laboratory of Dendritic Cell Biology, Department of Dermatology, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.
Deutsches Zentrum Immuntherapie (DZI), 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Medical Immunology Campus Erlangen, 91054 Erlangen, Germany.

Christoph Alexiou (C)

Department of Otorhinolaryngology, Head and Neck Surgery, Section of Experimental Oncology and Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung Professorship, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.

Christina Janko (C)

Department of Otorhinolaryngology, Head and Neck Surgery, Section of Experimental Oncology and Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung Professorship, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.

Classifications MeSH